Across TCGA pan-cancer cohorts, C15orf65 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C15orf65 data layer compared with 28 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher C15orf65 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C15orf65 expression acts as an unfavorable survival marker.
BRCA are the cancer types where C15orf65 Mutation most reproducibly stratifies survival.